18:11 , Jun 16, 2017 |  BioCentury  |  Product Development

Everywhere IDO

Incyte Corp. and partner Merck & Co. Inc. now have reported the data that led them to plan Phase III trials that combine their molecules in five cancer indications. For Incyte, the next step is...
22:39 , Apr 7, 2017 |  BioCentury  |  Finance

Fade to black

At the end of 2016, investors argued that equity values had nowhere to go but up. This proved to be the case in 1Q as all market cap bands finished in the black. Sector specialists,...
00:48 , Mar 30, 2017 |  BC Week In Review  |  Company News

Calithera, Incyte deal

Calithera will receive a $12 million milestone payment from Incyte under a January deal granting Incyte exclusive, worldwide rights to CB-1158 for hematology and cancer indications. Calithera said the milestone, the first under the deal,...
20:35 , Feb 3, 2017 |  BC Week In Review  |  Company News

Calithera, Incyte deal

Calithera granted Incyte exclusive, worldwide rights to CB-1158 for hematology and cancer indications. The arginase 1 (ARG1) and ARG2 inhibitor is in a Phase I/II trial to treat advanced or metastatic solid tumors, with data...
00:42 , Jan 31, 2017 |  BC Extra  |  Company News

Calithera surges on arginase deal with Incyte

Calithera Biosciences Inc. (NASDAQ:CALA) jumped $2.15 (47%) to $6.75 on Monday after granting Incyte Corp. (NASDAQ:INCY) worldwide rights to Calithera's CB-1158 for hematology and cancer indications. The arginase 1 (ARG1) and ARG2 inhibitor is in...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

CB-1158: Phase I started

Calithera began an open-label, U.S. Phase I trial to evaluate oral CB-1158 alone and in combination with an anti- PD-1 therapy in up to 236 patients. Calithera Biosciences Inc. (NASDAQ:CALA), South San Francisco, Calif.  ...